



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/12, C07K 14/715, C12N 15/62,</b> <b>G01N 33/566, C07K 16/28, 16/42</b>	<b>A1</b>	<b>(11) International Publication Number: WO 99/07848</b> <b>(43) International Publication Date: 18 February 1999 (18.02.99)</b>
<b>(21) International Application Number:</b> PCT/US98/15847 <b>(22) International Filing Date:</b> 30 July 1998 (30.07.98)  <b>(30) Priority Data:</b> 08/906,713 5 August 1997 (05.08.97) US  <b>(71) Applicant:</b> ZYMOGENETICS, INC. [US/US]; 1201 Eastlake Avenue East, Seattle, WA 98102 (US).  <b>(72) Inventors:</b> LOK, Si; 806 N.W. 52nd Street, Seattle, WA 98107 (US). ADAMS, Robyn, L.; 14418 S.E. 15th Street, Bellevue, WA 98007 (US). JELMBERG, Anna, C.; 170 2nd Avenue N.W. #203, Issaquah, WA 98027 (US). WHITEMORE, Theodore, E.; 6916 152nd Avenue N.E., Redmond, WA 98052 (US). FARRAH, Theresa, M.; 822 22nd Avenue, Seattle, WA 98122 (US).  <b>(74) Agent:</b> LUNN, Paul, G.; ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA 98102 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> MAMMALIAN CYTOKINE RECEPTOR-11  <b>(57) Abstract</b>  Novel receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise an extracellular domain of a cell-surface receptor that is expressed in pancreas, small intestine, colon and thymus. The polypeptides may be used within methods for detecting ligands that promote the proliferation and/or differentiation of these organs.		

**A11 - 09/608,918**

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

5

## MAMMALIAN CYTOKINE RECEPTOR - 11

## BACKGROUND OF THE INVENTION

Cytokines are soluble proteins that influence  
10 the growth and differentiation of many cell types. Their  
receptors are composed of one or more integral membrane  
proteins that bind the cytokine with high affinity and  
transduce this binding event to the cell through the  
cytoplasmic portions of the certain receptor subunits.  
15 Cytokine receptors have been grouped into several classes  
on the basis of similarities in their extracellular ligand  
binding domains. For example, the receptor chains  
responsible for binding and/or transducing the effect of  
interferons (IFNs) are members of the type II cytokine  
20 receptor family (CRF2), based upon a characteristic 200  
residue extracellular domain. The demonstrated *in vivo*  
activities of these interferons illustrate the enormous  
clinical potential of, and need for, other cytokines,  
cytokine agonists, and cytokine antagonists.

25

## SUMMARY OF THE INVENTION

The present invention fills this need by  
providing novel cytokine receptors and related  
30 compositions and methods. In particular, the present  
invention provides for an extracellular ligand-binding  
region of a mammalian Zcytor11 receptor, alternatively  
also containing either a transmembrane domain or both an  
intracellular domain and a transmembrane domain.

35

The present invention provides an isolated  
polynucleotide encoding a ligand-binding receptor

polypeptide. The polypeptide comprises a sequence of amino acids selected from the group consisting of (a) residues 18 to 228 of SEQ ID NO:2; (b) allelic variants of (a); and (c) sequences that are at least 80% identical to (a) or (b). Within one embodiment, the polypeptide comprises residues 18 to 228 of SEQ ID NO:2. Within another embodiment, the polypeptide encoded by the isolated polynucleotide further comprises a transmembrane domain. The transmembrane domain may comprise residues 229 to 251 of SEQ ID NO:2, or an allelic variant thereof. Within another embodiment, the polypeptide encoded by the isolated polynucleotide further comprises an intracellular domain, such as an intracellular domain comprising residues 252 to 574 of SEQ ID NO:2, or an allelic variant thereof. Within further embodiments, the polynucleotide encodes a polypeptide that comprises residues 1 to 574, 1 to 251, 1 to 228, 18 to 251 or 18 to 574 of SEQ ID NO:2. Within an additional embodiment, the polypeptide further comprises an affinity tag. Within a further embodiment, the polynucleotide is DNA.

Within another aspect of the invention there is provided an expression vector comprising (a) a transcription promoter; (b) a DNA segment encoding a ligand-binding receptor polypeptide, wherein the ligand-binding receptor polypeptide comprises a sequence of amino acids selected from the group consisting of: (i) residues 18-228 or any one of the residues described above of SEQ ID NO:2; (ii) allelic variants of (i); and (iii) sequences that are at least 80% identical to (i) or (ii); and (c) a transcription terminator, wherein the promoter, DNA segment, and terminator are operably linked. The ligand-binding receptor polypeptide may further comprise a secretory peptide, a transmembrane domain, a transmembrane domain and an intracellular domain, or a secretory

peptide, a transmembrane domain and an intracellular domain.

Within another aspect of the invention there is  
5 provided a cultured eukaryotic cell into which has been introduced an expression vector as disclosed above, wherein said cell expresses a receptor polypeptide encoded by the DNA segment. Within one embodiment, the cell further expresses a necessary receptor subunit which forms  
10 a functional receptor complex. Within another embodiment, the cell is dependent upon an exogenously supplied hematopoietic growth factor for proliferation.

Within another aspect of the invention there is  
15 provided an isolated polypeptide comprising a segment selected from the group consisting of (a) residues 18 to 228 of SEQ ID NO:2, also disclosed as SEQ ID NO:9; (b) allelic variants of (a); and (c) sequences that are at least 80% identical to (a) or (b), wherein said  
20 polypeptide is substantially free of transmembrane and intracellular domains ordinarily associated with hematopoietic receptors. Additional polypeptides of the present invention include Within one embodiment, the polypeptide comprises residues 18 to 228 of SEQ ID NO:2.  
25 Within another embodiment, the polypeptide further comprises a transmembrane domain. The transmembrane domain may comprise residues 229 to 251 of SEQ ID NO:2, also disclosed as SEQ ID NO:10, or an allelic variant thereof. Within another embodiment, the polypeptide  
30 further comprises an intracellular domain, such as an intracellular domain comprising residues 252 to 574 of SEQ ID NO:2, also disclosed as SEQ ID NO: 11, or an allelic variant thereof. Within further embodiments the polypeptide that comprises residues 1 to 574, 1 to 251, 1  
35 to 228, 18 to 251 or 18 to 574 of SEQ ID NO:2.

Within one embodiment, the polypeptide further comprises an immunoglobulin F<sub>C</sub> polypeptide. Within a another embodiment, the polypeptide further comprises an affinity tag, such as polyhistidine, protein A,  
5 glutathione S transferase, or an immunoglobulin heavy chain constant region.

Within a further aspect of the invention there is provided a chimeric polypeptide consisting essentially  
10 of a first portion and a second portion joined by a peptide bond. The first portion of the chimeric polypeptide consists essentially of a ligand binding domain of a receptor polypeptide selected from the group consisting of (a) a receptor polypeptide as shown in SEQ  
15 ID NO:2; (b) allelic variants of SEQ ID NO:2; and (c) receptor polypeptides that are at least 80% identical to (a) or (b). The second portion of the chimeric polypeptide consists essentially of an affinity tag. Within one embodiment the affinity tag is an  
20 immunoglobulin F<sub>C</sub> polypeptide. The invention also provides expression vectors encoding the chimeric polypeptides and host cells transfected to produce the chimeric polypeptides.

25 The present invention also provides for an isolated polynucleotide encoding a polypeptide selected from a group defined SEQ ID NO:2 consisting of residues 1 to 228, residues 1 to 251, residues 1 to 574, residues 2 to 228, residues 2 to 251 and residues 2 to 574. Also  
30 claimed are the isolated polypeptide expressed by these polynucleotides.

The invention also provides a method for detecting a ligand within a test sample, comprising  
35 contacting a test sample with a polypeptide as disclosed above, and detecting binding of the polypeptide to ligand

in the sample. Within one embodiment the polypeptide further comprises transmembrane and intracellular domains. The polypeptide can be membrane bound within a cultured cell, wherein the detecting step comprises measuring a  
5 biological response in the cultured cell. Within another embodiment, the polypeptide is immobilized on a solid support.

Within an additional aspect of the invention  
10 there is provided an antibody that specifically binds to a polypeptide as disclosed above, as well as an anti-idiotypic antibody which binds to the antigen-binding region of an antibody to Zcytor11.

15 In still another aspect of the present invention, polynucleotide primers and probes are provided which can detect mutations in the Zcytor11 gene. The polynucleotide probe should at least be 20-25 bases in length, preferably at least 50 bases in length and most  
20 preferably about 80 to 100 bases in length. In addition to the detection of mutations, these probes can be used to discover the Zcytor11 gene in other mammalian species. The probes can either be positive strand or anti-sense strands, and they can be comprised of DNA or RNA.

25 An additional embodiment of the present invention relates to a peptide or polypeptide which has the amino acid sequence of an epitope-bearing portion of a Zcytor11 polypeptide having an amino acid sequence  
30 described above. Peptides or polypeptides having the amino acid sequence of an epitope-bearing portion of a Zcytor11 polypeptide of the present invention include portions of such polypeptides with at least nine, preferably at least 15 and more preferably at least 30 to 50 amino acids,  
35 although epitope-bearing polypeptides of any length up to and including the entire amino acid sequence of a

polypeptide of the present invention described above are also included in the present invention. Examples of said polypeptides are defined by the amino acid sequences of SEQ ID NOs: 7 and 8. Also claimed are any of these  
5 polypeptides that are fused to another polypeptide or carrier molecule.

Further embodiments of the invention include isolated nucleic acid molecules that comprise a  
10 polynucleotide having a nucleotide sequence at least 90% identical, and more preferably 95%, 97%, 98%, or 99% identical to any of the nucleotide described above, or a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide having a  
15 nucleotide sequence described above. An additional nucleic acid embodiment of the present invention relates to an isolated nucleic acid molecule comprising an amino acid of an epitope-bearing portion of a Zcytor11 polypeptide.

20

These and other aspects of the invention will become evident upon reference to the following detailed description and the attached drawing.

25

#### DETAILED DESCRIPTION OF THE INVENTION

The term "allelic variant" is used herein to denote any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation  
30 arises naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequence. The term allelic variant is also  
35 used herein to denote a protein encoded by an allelic variant of a gene.



The term "expression vector" is used to denote a DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to  
5 additional segments that provide for its transcription. Such additional segments include promoter and terminator sequences, and may also include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, etc. Expression vectors are  
10 generally derived from plasmid or viral DNA, or may contain elements of both.

The term "isolated", when applied to a polynucleotide, denotes that the polynucleotide has been  
15 removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems.

20 "Operably linked", when referring to DNA segments, indicates that the segments are arranged so that they function in concert for their intended purposes, e.g. transcription initiates in the promoter and proceeds through the coding segment to the terminator.

25 A "polynucleotide" is a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and may be isolated from natural  
30 sources, synthesized *in vitro*, or prepared from a combination of natural and synthetic molecules.

The term "promoter" is used herein for its art-recognized meaning to denote a portion of a gene  
35 containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter

sequences are commonly, but not always, found in the 5' non-coding regions of genes.

The term "receptor" is used herein to denote a cell-associated protein, or a polypeptide subunit of such a protein, that binds to a bioactive molecule (the "ligand") and mediates the effect of the ligand on the cell. Binding of ligand to receptor results in a conformational change in the receptor (and, in some cases, receptor multimerization, i.e., association of identical or different receptor subunits) that causes interactions between the effector domain(s) and other molecule(s) in the cell. These interactions in turn lead to alterations in the metabolism of the cell. Metabolic events that are linked to receptor-ligand interactions include gene transcription, phosphorylation, dephosphorylation, cell proliferation, increases in cyclic AMP production, mobilization of cellular calcium, mobilization of membrane lipids, cell adhesion, hydrolysis of inositol lipids and hydrolysis of phospholipids. The term "receptor polypeptide" is used to denote complete receptor polypeptide chains and portions thereof, including isolated functional domains (e.g., ligand-binding domains).

A "secretory signal sequence" is a DNA sequence that encodes a polypeptide (a "secretory peptide") that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized. The larger polypeptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.

A "soluble receptor" is a receptor polypeptide that is not bound to a cell membrane. Soluble receptors are most commonly ligand-binding receptor polypeptides

that lack transmembrane and cytoplasmic domains. Soluble receptors can comprise additional amino acid residues, such as affinity tags that provide for purification of the polypeptide or provide sites for attachment of the polypeptide to a substrate, or immunoglobulin constant region sequences. Many cell-surface receptors have naturally occurring, soluble counterparts that are produced by proteolysis or translated from alternatively spliced mRNAs. Receptor polypeptides are said to be substantially free of transmembrane and intracellular polypeptide segments when they lack sufficient portions of these segments to provide membrane anchoring or signal transduction, respectively.

Analysis of the tissue distribution of the mRNA corresponding to this novel DNA showed that mRNA level was highest in pancreas, followed by a much lower levels in thymus, colon and small intestine. The receptor has been designated "Zcytor11".

Cytokine receptors subunits are characterized by a multi-domain structure comprising a ligand-binding domain and an effector domain that is typically involved in signal transduction. Multimeric cytokine receptors include homodimers (e.g., PDGF receptor  $\alpha\alpha$  and  $\beta\beta$  isoforms, erythropoietin receptor, MPL [thrombopoietin receptor], and G-CSF receptor), heterodimers whose subunits each have ligand-binding and effector domains (e.g., PDGF receptor  $\alpha\beta$  isoform), and multimers having component subunits with disparate functions (e.g., IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, and GM-CSF receptors). Some receptor subunits are common to a plurality of receptors. For example, the AIC2B subunit, which cannot bind ligand on its own but includes an intracellular signal transduction domain, is a component of IL-3 and GM-CSF receptors. Many cytokine receptors can be placed into one

of four related families on the basis of their structures and functions. Class I hematopoietic receptors, for example, are characterized by the presence of a domain containing conserved cysteine residues and the WSXWS motif. Additional domains, including protein kinase domains; fibronectin type III domains; and immunoglobulin domains, which are characterized by disulfide-bonded loops, are present in certain hematopoietic receptors. Cytokine receptor structure has been reviewed by Urdal, *Ann. Reports Med. Chem.* 26:221-228 (1991) and Cosman, *Cytokine* 5:95-106 (1993). It is generally believed that under selective pressure for organisms to acquire new biological functions, new receptor family members arose from duplication of existing receptor genes leading to the existence of multi-gene families. Family members thus contain vestiges of the ancestral gene, and these characteristic features can be exploited in the isolation and identification of additional family members.

Cell-surface cytokine receptors are further characterized by the presence of additional domains. These receptors are anchored in the cell membrane by a transmembrane domain characterized by a sequence of hydrophobic amino acid residues (typically about 21-25 residues), which is commonly flanked by positively charged residues (Lys or Arg). On the opposite end of the protein from the extracellular domain and separated from it by the transmembrane domain is an intracellular domain.

The novel receptor of the present invention, Zcytor11, is a class II cytokine receptor. These receptors usually bind to four-helix-bundle cytokines. Interleukin-10 and the interferons have receptors in this class (e.g., interferon-gamma alpha and beta chains and the interferon-alpha/beta receptor alpha and beta chains). Class II cytokine receptors are characterized by the presence of

one or more cytokine receptor modules (CRM) in their extracellular domains. The CRMs of class II cytokine receptors are somewhat different than the better known CRMs of class I cytokine receptors. While the class II  
5 CRMs contain two type-III fibronectin-like domains, they differ in organization.

Zcytor11, like all known class II receptors except interferon-alpha/beta receptor alpha chain, has  
10 only a single class II CRM in its extracellular domain. Zcytor11 appears to be a receptor for a helical cytokine of the interferon/IL-10 class. Using the Zcytor11 receptor we can identify ligands and additional compounds which would be of significant therapeutic value.

15

As was stated above, Zcytor11 is similar to the interferon  $\alpha$  receptor  $\alpha$  chain. Uze et al. *Cell* 60 255-264 (1996) Analysis of a human cDNA clone encoding Zcytor11 (SEQ ID NO:1) revealed an open reading frame encoding 574  
20 amino acids (SEQ ID NO:2) comprising an extracellular ligand-binding domain of approximately 211 amino acid residues (residues 18-228 of SEQ ID NO:2), a transmembrane domain of approximately 23 amino acid residues (residues 229-251 of SEQ ID NO:2), and an intracellular domain of  
25 approximately 313 amino acid residues (residues 252 to 574 of SEQ ID NO:2). Those skilled in the art will recognize that these domain boundaries are approximate and are based on alignments with known proteins and predictions of protein folding. Deletion of residues from the ends of  
30 the domains is possible.

Within preferred embodiments of the invention the isolated polynucleotides will hybridize to similar sized regions of SEQ ID NO:1 or a sequence complementary  
35 thereto, under stringent conditions. In general, stringent conditions are selected to be about 5°C lower

than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Typical stringent conditions are those in which the salt concentration is which the salt concentration is up to about 0.03 M at pH 7 and the temperature is at least about 60°C. As previously noted, the isolated polynucleotides of the present invention include DNA and RNA. Methods for isolating DNA and RNA are well known in the art. It is generally preferred to isolate RNA from pancreas or prostate tissues although cDNA can also be prepared using RNA from other tissues or isolated as genomic DNA. Total RNA can be prepared using guanidine HCl extraction followed by isolation by centrifugation in a CsCl gradient [Chirgwin et al., *Biochemistry* 18:52-94, (1979)]. Poly (A)<sup>+</sup> RNA is prepared from total RNA using the method of Aviv and Leder *Proc. Natl. Acad. Sci. USA* 69:1408-1412, (1972). Complementary DNA (cDNA) is prepared from poly(A)<sup>+</sup> RNA using known methods. Polynucleotides encoding Zcytor11 polypeptides are then identified and isolated by, for example, hybridization or PCR.

Those skilled in the art will recognize that the sequences disclosed in SEQ ID NOS:1 and 2 represent single alleles of the human Zcytor11 receptor. Allelic variants of these sequences can be cloned by probing cDNA or genomic libraries from different individuals according to standard procedures.

The present invention further provides counterpart receptors and polynucleotides from other species ("species orthologs"). Of particular interest are Zcytor11 receptors from other mammalian species, including murine, porcine, ovine, bovine, canine, feline, equine,

and non-human primates. Species orthologs of the human Zcytor11 receptor can be cloned using information and compositions provided by the present invention in combination with conventional cloning techniques. For example, a cDNA can be cloned using mRNA obtained from a tissue or cell type that expresses the receptor. Suitable sources of mRNA can be identified by probing Northern blots with probes designed from the sequences disclosed herein. A library is then prepared from mRNA of a positive tissue or cell line. A receptor-encoding cDNA can then be isolated by a variety of methods, such as by probing with a complete or partial cDNA of human and other primates or with one or more sets of degenerate probes based on the disclosed sequences. A cDNA can also be cloned using the polymerase chain reaction, or PCR (Mullis, U.S. Patent No. 4,683,202), using primers designed from the sequences disclosed herein. Within an additional method, the cDNA library can be used to transform or transfect host cells, and expression of the cDNA of interest can be detected with an antibody to the receptor. Similar techniques can also be applied to the isolation of genomic clones.

The present invention also provides isolated receptor polypeptides that are substantially homologous to the receptor polypeptide of SEQ ID NO: 2. By "isolated" is meant a protein or polypeptide that is found in a condition other than its native environment, such as apart from blood and animal tissue. In a preferred form, the isolated polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin. It is preferred to provide the polypeptides in a highly purified form, i.e. greater than 95% pure, more preferably greater than 99% pure. The term "substantially homologous" is used herein to denote polypeptides having 50%, preferably 60%, more preferably at least 80%,

sequence identity to the sequences shown in SEQ ID NO:2,.  
Such polypeptides will more preferably be at least 90%  
identical, and most preferably 95% or more identical to  
SEQ ID NO:2. Percent sequence identity is determined by  
5 conventional methods. See, for example, Altschul et al.,  
*Bull. Math. Bio.* 48: 603-616, (1986) and Henikoff and  
Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915-10919,  
(1992). Briefly, two amino acid sequences are aligned to  
optimize the alignment scores using a gap opening penalty  
10 of 10, a gap extension penalty of 1, and the "blossom 62"  
scoring matrix of Henikoff and Henikoff (*id.*) as shown in  
Table 1 (amino acids are indicated by the standard one-  
letter codes). The percent identity is then calculated  
as:

15

$$\frac{\text{Total number of identical matches}}{[\text{length of the longer sequence plus the} \\ \text{number of gaps introduced into the longer} \\ \text{sequence in order to align the two} \\ \text{sequences}]} \times 100$$

20



Table 1

	A	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W	Y	V	
5	A	4																			
	R	-1	5																		
	N	-2	0	6																	
	D	-2	-2	1	6																
	C	0	-3	-3	-3	9															
	Q	-1	1	0	0	-3	5														
10	E	-1	0	0	2	-4	2	5													
	G	0	-2	0	-1	-3	-2	-2	6												
	H	-2	0	1	-1	-3	0	0	-2	8											
	I	-1	-3	-3	-3	-1	-3	-3	-4	-3	4										
	L	-1	-2	-3	-4	-1	-2	-3	-4	-3	2	4									
15	K	-1	2	0	-1	-3	1	1	-2	-1	-3	-2	5								
	M	-1	-1	-2	-3	-1	0	-2	-3	-2	1	2	-1	5							
	F	-2	-3	-3	-3	-2	-3	-3	-3	-1	0	0	-3	0	6						
	P	-1	-2	-2	-1	-3	-1	-1	-2	-2	-3	-3	-1	-2	-4	7					
	S	1	-1	1	0	-1	0	0	0	-1	-2	-2	0	-1	-2	-1	4				
20	T	0	-1	0	-1	-1	-1	-1	-2	-2	-1	-1	-1	-2	-1	1	5				
	W	-3	-3	-4	-4	-2	-2	-3	-2	-2	-3	-2	-3	-1	1	-4	-3	-2	11		
	Y	-2	-2	-2	-3	-2	-1	-2	-3	2	-1	-1	-2	-1	3	-3	-2	-2	2	7	
	V	0	-3	-3	-3	-1	-2	-2	-3	-3	3	1	-2	1	-1	-2	2	0	-3	-1	4

Sequence identity of polynucleotide molecules is determined by similar methods using a ratio as disclosed above.

5           Substantially homologous proteins and polypeptides are characterized as having one or more amino acid substitutions, deletions or additions. These changes are preferably of a minor nature, that is conservative amino acid substitutions (see Table 2) and other substitutions  
10 that do not significantly affect the folding or activity of the protein or polypeptide; small deletions, typically of one to about 30 amino acids; and small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about  
15 20-25 residues, or a small extension that facilitates purification (an affinity tag), such as a poly-histidine tract, protein A [Nilsson et al., *EMBO J.* 4:1075, (1985); Nilsson et al., *Methods Enzymol.* 198:3, (1991)], glutathione S transferase [Smith and Johnson, *Gene* 67:31,  
20 1988), or other antigenic epitope or binding domain. See, in general Ford et al., *Protein Expression and Purification* 2: 95-107 (1991). DNAs encoding affinity tags are available from commercial suppliers (e.g., Pharmacia Biotech, Piscataway, NJ).

25

Table 2

Conservative amino acid substitutions

30	Basic:	arginine
		lysine
		histidine
	Acidic:	glutamic acid
		aspartic acid
	Polar:	glutamine
		asparagine

Table 2, continued

	Hydrophobic:	leucine
		isoleucine
		valine
5	Aromatic:	phenylalanine
		tryptophan
		tyrosine
	Small:	glycine
10		alanine
		serine
		threonine
		methionine
15	Essential amino acids in the receptor	
	polypeptides of the present invention can be identified	
	according to procedures known in the art, such as site-	
	directed mutagenesis or alanine-scanning mutagenesis	
	[Cunningham and Wells, <i>Science</i> 244, 1081-1085, (1989);	
20	Bass et al., <i>Proc. Natl. Acad. Sci. USA</i> 88:4498-4502,	
	(1991)]. In the latter technique, single alanine	
	mutations are introduced at every residue in the molecule,	
	and the resultant mutant molecules are tested for	
	biological activity (e.g., ligand binding and signal	
25	transduction) to identify amino acid residues that are	
	critical to the activity of the molecule. Sites of	
	ligand-receptor interaction can also be determined by	
	analysis of crystal structure as determined by such	
	techniques as nuclear magnetic resonance, crystallography	
30	or photoaffinity labeling. See, for example, de Vos et	
	al., <i>Science</i> 255:306-312, (1992); Smith et al., <i>J. Mol.</i>	
	<i>Biol.</i> 224:899-904, (1992); Wlodaver et al., <i>FEBS Lett.</i>	
	309:59-64, (1992)]. The identities of essential amino	
	acids can also be inferred from analysis of homologies	
35	with related receptors.	

Multiple amino acid substitutions can be made and tested using known methods of mutagenesis and screening, such as those disclosed by Reidhaar-Olson and Sauer *Science* 241:53-57, (1988) or Bowie and Sauer *Proc. Natl. Acad. Sci. USA* 86:2152-2156, (1989). Briefly, these authors disclose methods for simultaneously randomizing two or more positions in a polypeptide, selecting for functional polypeptide, and then sequencing the mutagenized polypeptides to determine the spectrum of allowable substitutions at each position. Other methods that can be used include phage display e.g., Lowman et al., *Biochem.* 30:10832-10837, (1991); Ladner et al., U.S. Patent No. 5,223,409; Huse, WIPO Publication WO 92/06204) and region-directed mutagenesis [Derbyshire et al., *Gene* 15 46:145, (1986); Ner et al., *DNA* 7:127, (1988)].

Mutagenesis methods as disclosed above can be combined with high-throughput screening methods to detect activity of cloned, mutagenized receptors in host cells. Preferred assays in this regard include cell proliferation assays and biosensor-based ligand-binding assays, which are described below. Mutagenized DNA molecules that encode active receptors or portions thereof (e.g., ligand-binding fragments) can be recovered from the host cells and rapidly sequenced using modern equipment. These methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide of interest, and can be applied to polypeptides of unknown structure.

30

Using the methods discussed above, one of ordinary skill in the art can prepare a variety of polypeptides that are substantially homologous to residues 18 to 228 of SEQ ID NO:2 or allelic variants thereof and retain the ligand-binding properties of the wild-type receptor. Such polypeptides may include additional amino

35

acids from an extracellular ligand-binding domain of a Zcytor11 receptor as well as part or all of the transmembrane and intracellular domains. Such polypeptides may also include additional polypeptide segments as generally disclosed above.

The receptor polypeptides of the present invention, including full-length receptors, receptor fragments (e.g. ligand-binding fragments), and fusion polypeptides can be produced in genetically engineered host cells according to conventional techniques. Suitable host cells are those cell types that can be transformed or transfected with exogenous DNA and grown in culture, and include bacteria, fungal cells, and cultured higher eukaryotic cells. Eukaryotic cells, particularly cultured cells of multicellular organisms, are preferred. Techniques for manipulating cloned DNA molecules and introducing exogenous DNA into a variety of host cells are disclosed by Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989), and Ausubel et al., *ibid.*, which are incorporated herein by reference.

In general, a DNA sequence encoding a Zcytor11 receptor polypeptide is operably linked to other genetic elements required for its expression, generally including a transcription promoter and terminator, within an expression vector. The vector will also commonly contain one or more selectable markers and one or more origins of replication, although those skilled in the art will recognize that within certain systems selectable markers may be provided on separate vectors, and replication of the exogenous DNA may be provided by integration into the host cell genome. Selection of promoters, terminators, selectable markers, vectors and other elements is a matter of routine design within the level of ordinary skill in

the art. Many such elements are described in the literature and are available through commercial suppliers.

To direct a Zcytor11 receptor polypeptide into  
5 the secretory pathway of a host cell, a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) is provided in the expression vector. The secretory signal sequence may be that of the receptor, or may be derived from another secreted protein (e.g., t-  
10 PA) or synthesized *de novo*. The secretory signal sequence is joined to the Zcytor11 DNA sequence in the correct reading frame. Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the polypeptide of interest, although certain signal sequences may be  
15 positioned elsewhere in the DNA sequence of interest (see, e.g., Welch et al., U.S. Patent No. 5,037,743; Holland et al., U.S. Patent No. 5,143,830).

Another embodiment of the present invention  
20 provides for a peptide or polypeptide comprising an epitope-bearing portion of a polypeptide of the invention. The epitope of the this polypeptide portion is an immunogenic or antigenic epitope of a polypeptide of the invention. A region of a protein to which an antibody can  
25 bind is defined as an "antigenic epitope". See for instance, Geysen, H.M. et al., *Proc. Natl. Acad Sci. USA* 81:3998-4002 (1984).

As to the selection of peptides or polypeptides  
30 bearing an antigenic epitope (i.e., that contain a region of a protein molecule to which an antibody can bind), it is well known in the art that relatively short synthetic peptides that mimic part of a protein sequence are routinely capable of eliciting an antiserum that reacts  
35 with the partially mimicked protein. See Sutcliffe, J.G. et al. *Science* 219:660-666 (1983). Peptides capable of

eliciting protein-reactive sera are frequently represented in the primary sequence of a protein, can be characterized by a set of simple chemical rules, and are confined neither to immunodominant regions of intact proteins  
5 (i.e., immunogenic epitopes) nor to the amino or carboxyl terminals. Peptides that are extremely hydrophobic and those of six or fewer residues generally are ineffective at inducing antibodies that bind to the mimicked protein; longer soluble peptides, especially those containing  
10 proline residues, usually are effective.

Antigenic epitope-bearing peptides and polypeptides of the invention are therefore useful to raise antibodies, including monoclonal antibodies, that  
15 bind specifically to a polypeptide of the invention. Antigenic epitope-bearing peptides and polypeptides of the present invention contain a sequence of at least nine, preferably between 15 to about 30 amino acids contained within the amino acid sequence of a polypeptide of the  
20 invention. However, peptides or polypeptides comprising a larger portion of an amino acid sequence of the invention, containing from 30 to 50 amino acids, or any length up to and including the entire amino acid sequence of a polypeptide of the invention, also are useful for inducing  
25 antibodies that react with the protein. Preferably, the amino acid sequence of the epitope-bearing peptide is selected to provide substantial solubility in aqueous solvents (i.e., the sequence includes relatively hydrophilic residues and hydrophobic residues are  
30 preferably avoided); and sequences containing proline residues are particularly preferred. All of the polypeptides shown in the sequence listing contain antigenic epitopes to be used according to the present invention, however, specifically designed antigenic  
35 epitopes include the peptides defined by SEQ ID NOs: 7 and 8.

Cultured mammalian cells are preferred hosts within the present invention. Methods for introducing exogenous DNA into mammalian host cells include calcium phosphate-mediated transfection [Wigler et al., *Cell* 14:725, (1978); Corsaro and Pearson, *Somatic Cell Genetics* 7:603, (1981); Graham and Van der Eb, *Virology* 52:456, (1973)], electroporation [Neumann et al., *EMBO J.* 1:841-845, (1982)], DEAE-dextran mediated transfection [Ausubel et al., eds., *Current Protocols in Molecular Biology*, (John Wiley and Sons, Inc., NY, 1987), and liposome-mediated transfection (Hawley-Nelson et al., *Focus* 15:73, (1993); Ciccarone et al., *Focus* 15:80, (1993)], which are incorporated herein by reference. The production of recombinant polypeptides in cultured mammalian cells is disclosed, for example, by Levinson et al., U.S. Patent No. 4,713,339; Hagen et al., U.S. Patent No. 4,784,950; Palmiter et al., U.S. Patent No. 4,579,821; and Ringold, U.S. Patent No. 4,656,134. Suitable cultured mammalian cells include the COS-1 (ATCC No. CRL 1650), COS-7 (ATCC No. CRL 1651), BHK (ATCC No. CRL 1632), BHK 570 (ATCC No. CRL 10314), 293 (ATCC No. CRL 1573; Graham et al., *J. Gen. Virol.* 36:59-72, 1977) and Chinese hamster ovary (e.g. CHO-K1; ATCC No. CCL 61) cell lines. Additional suitable cell lines are known in the art and available from public depositories such as the American Type Culture Collection, Rockville, Maryland. In general, strong transcription promoters are preferred, such as promoters from SV-40 or cytomegalovirus. See, e.g., U.S. Patent No. 4,956,288. Other suitable promoters include those from metallothionein genes (U.S. Patent Nos. 4,579,821 and 4,601,978) and the adenovirus major late promoter.

Drug selection is generally used to select for cultured mammalian cells into which foreign DNA has been



inserted. Such cells are commonly referred to as "transfectants". Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as

5 "stable transfectants." A preferred selectable marker is a gene encoding resistance to the antibiotic neomycin. Selection is carried out in the presence of a neomycin-type drug, such as G-418 or the like. Selection systems may also be used to increase the expression level of the

10 gene of interest, a process referred to as "amplification." Amplification is carried out by culturing transfectants in the presence of a low level of the selective agent and then increasing the amount of selective agent to select for cells that produce high

15 levels of the products of the introduced genes. A preferred amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate. Other drug resistance genes (e.g. hygromycin resistance, multi-drug resistance, puromycin acetyltransferase) can

20 also be used.

Other higher eukaryotic cells can also be used as hosts, including insect cells, plant cells and avian cells. Transformation of insect cells and production of

25 foreign polypeptides therein is disclosed by Guarino et al., U.S. Patent No. 5,162,222; Bang et al., U.S. Patent No. 4,775,624; and WIPO publication WO 94/06463, which are incorporated herein by reference. The use of

*Agrobacterium rhizogenes* as a vector for expressing genes

30 in plant cells has been reviewed by Sinkar et al., *J. Biosci. (Bangalore)* 11:47-58, (1987).

Fungal cells, including yeast cells, and particularly cells of the genus *Saccharomyces*, can also be

35 used within the present invention, such as for producing receptor fragments or polypeptide fusions. Methods for

transforming yeast cells with exogenous DNA and producing recombinant polypeptides therefrom are disclosed by, for example, Kawasaki, U.S. Patent No. 4,599,311; Kawasaki et al., U.S. Patent No. 4,931,373; Brake, U.S. Patent No. 4,870,008; Welch et al., U.S. Patent No. 5,037,743; and Murray et al., U.S. Patent No. 4,845,075. Transformed cells are selected by phenotype determined by the selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient (e.g., leucine). A preferred vector system for use in yeast is the POT1 vector system disclosed by Kawasaki et al. (U.S. Patent No. 4,931,373), which allows transformed cells to be selected by growth in glucose-containing media. Suitable promoters and terminators for use in yeast include those from glycolytic enzyme genes (see, e.g., Kawasaki, U.S. Patent No. 4,599,311; Kingsman et al., U.S. Patent No. 4,615,974; and Bitter, U.S. Patent No. 4,977,092) and alcohol dehydrogenase genes. See also U.S. Patents Nos. 4,990,446; 5,063,154; 5,139,936 and 4,661,454. Transformation systems for other yeasts, including *Hansenula polymorpha*, *Schizosaccharomyces pombe*, *Kluyveromyces lactis*, *Kluyveromyces fragilis*, *Ustilago maydis*, *Pichia pastoris*, *Pichia methanolica*, *Pichia guilliermondii* and *Candida maltosa* are known in the art. See, for example, Gleeson et al., *J. Gen. Microbiol.* 132:3459-3465, (1986) and Cregg, U.S. Patent No. 4,882,279. *Aspergillus* cells may be utilized according to the methods of McKnight et al., U.S. Patent No. 4,935,349. Methods for transforming *Acremonium chrysogenum* are disclosed by Sumino et al., U.S. Patent No. 5,162,228. Methods for transforming *Neurospora* are disclosed by Lambowitz, U.S. Patent No. 4,486,533.

Transformed or transfected host cells are cultured according to conventional procedures in a culture medium containing nutrients and other components required

for the growth of the chosen host cells. A variety of suitable media, including defined media and complex media, are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals. Media may also contain such components as growth factors or serum, as required. The growth medium will generally select for cells containing the exogenously added DNA by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker carried on the expression vector or co-transfected into the host cell.

Within one aspect of the present invention, a novel receptor is produced by a cultured cell, and the cell is used to screen for ligands for the receptor, including the natural ligand, as well as agonists and antagonists of the natural ligand. To summarize this approach, a cDNA or gene encoding the receptor is combined with other genetic elements required for its expression (e.g., a transcription promoter), and the resulting expression vector is inserted into a host cell. Cells that express the DNA and produce functional receptor are selected and used within a variety of screening systems.

Mammalian cells suitable for use in expressing Zcytor11 receptors and transducing a receptor-mediated signal include cells that express other receptor subunits which may form a functional complex with Zcytor11. These subunits may include those of the interferon receptor family or of other class II or class I cytokine receptors. It is also preferred to use a cell from the same species as the receptor to be expressed. Within a preferred embodiment, the cell is dependent upon an exogenously supplied hematopoietic growth factor for its proliferation. Preferred cell lines of this type are the human TF-1 cell line (ATCC number CRL-2003) and the AML-

193 cell line (ATCC number CRL-9589), which are GM-CSF-dependent human leukemic cell lines and BaF3 [Palacios and Steinmetz, *Cell* 41: 727-734, (1985)] which is an IL-3 dependent murine pre-B cell line. Other cell lines include  
5 BHK, COS-1 and CHO cells.

Suitable host cells can be engineered to produce the necessary receptor subunits or other cellular component needed for the desired cellular response. This  
10 approach is advantageous because cell lines can be engineered to express receptor subunits from any species, thereby overcoming potential limitations arising from species specificity. Species orthologs of the human receptor cDNA can be cloned and used within cell lines  
15 from the same species, such as a mouse cDNA in the BaF3 cell line. Cell lines that are dependent upon one hematopoietic growth factor, such as GM-CSF or IL-3, can thus be engineered to become dependent upon a Zcytor11 ligand.

20

Cells expressing functional receptor are used within screening assays. A variety of suitable assays are known in the art. These assays are based on the detection of a biological response in a target cell. One such assay  
25 is a cell proliferation assay. Cells are cultured in the presence or absence of a test compound, and cell proliferation is detected by, for example, measuring incorporation of tritiated thymidine or by colorimetric assay based on the metabolic breakdown of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide  
30 (MTT) [Mosman, *J. Immunol. Meth.* 65: 55-63, (1983)]. An alternative assay format uses cells that are further engineered to express a reporter gene. The reporter gene is linked to a promoter element that is responsive to the  
35 receptor-linked pathway, and the assay detects activation of transcription of the reporter gene. A preferred

promoter element in this regard is a serum response element, or SRE. See, e.g., Shaw et al., *Cell* 56:563-572, (1989). A preferred such reporter gene is a luciferase gene [de Wet et al., *Mol. Cell. Biol.* 7:725, (1987)].

- 5 Expression of the luciferase gene is detected by luminescence using methods known in the art [e.g., Baumgartner et al., *J. Biol. Chem.* 269:29094-29101, (1994); Schenborn and Goiffin, *Promega\_Notes* 41:11, 1993). Luciferase activity assay kits are commercially available
- 10 from, for example, Promega Corp., Madison, WI. Target cell lines of this type can be used to screen libraries of chemicals, cell-conditioned culture media, fungal broths, soil samples, water samples, and the like. For example, a bank of cell-conditioned media samples can be assayed on a
- 15 target cell to identify cells that produce ligand. Positive cells are then used to produce a cDNA library in a mammalian expression vector, which is divided into pools, transfected into host cells, and expressed. Media samples from the transfected cells are then assayed, with
- 20 subsequent division of pools, re-transfection, subculturing, and re-assay of positive cells to isolate a cloned cDNA encoding the ligand.

- A natural ligand for the Zcytor11 receptor can
- 25 also be identified by mutagenizing a cell line expressing the receptor and culturing it under conditions that select for autocrine growth. See WIPO publication WO 95/21930. Within a typical procedure, IL-3 dependent BaF3 cells expressing Zcytor11 and the necessary additional subunits
- 30 are mutagenized, such as with 2-ethylmethanesulfonate (EMS). The cells are then allowed to recover in the presence of IL-3, then transferred to a culture medium lacking IL-3 and IL-4. Surviving cells are screened for the production of a Zcytor11 ligand, such as by adding
- 35 soluble receptor to the culture medium or by assaying

conditioned media on wild-type BaF3 cells and BaF3 cells expressing the receptor.

An additional screening approach provided by the present invention includes the use of hybrid receptor polypeptides. These hybrid polypeptides fall into two general classes. Within the first class, the intracellular domain of Zcytor11, comprising approximately residues 252 to 574 of SEQ ID NO:2, is joined to the ligand-binding domain of a second receptor. It is preferred that the second receptor be a hematopoietic cytokine receptor, such as mpl receptor [Souyri et al., *Cell* 63: 1137-1147, (1990)]. The hybrid receptor will further comprise a transmembrane domain, which may be derived from either receptor. A DNA construct encoding the hybrid receptor is then inserted into a host cell. Cells expressing the hybrid receptor are cultured in the presence of a ligand for the binding domain and assayed for a response. This system provides a means for analyzing signal transduction mediated by Zcytor11 while using readily available ligands. This system can also be used to determine if particular cell lines are capable of responding to signals transduced by Zcytor11. A second class of hybrid receptor polypeptides comprise the extracellular (ligand-binding) domain of Zcytor11 (approximately residues 18 to 228 of SEQ ID NO:2) with an intracellular domain of a second receptor, preferably a hematopoietic cytokine receptor, and a transmembrane domain. Hybrid receptors of this second class are expressed in cells known to be capable of responding to signals transduced by the second receptor. Together, these two classes of hybrid receptors enable the identification of a responsive cell type for the development of an assay for detecting a Zcytor11 ligand.

Cells found to express the ligand are then used to prepare a cDNA library from which the ligand-encoding cDNA can be isolated as disclosed above. The present invention thus provides, in addition to novel receptor polypeptides, methods for cloning polypeptide ligands for the receptors.

The tissue specificity of Zcytor11 expression suggests a role in the development of the pancreas, small intestine, colon and the thymus. In view of the tissue specificity observed for this receptor, agonists (including the natural ligand) and antagonists have enormous potential in both *in vitro* and *in vivo* applications. Compounds identified as receptor agonists are useful for stimulating proliferation and development of target cells *in vitro* and *in vivo*. For example, agonist compounds are useful as components of defined cell culture media, and may be used alone or in combination with other cytokines and hormones to replace serum that is commonly used in cell culture. Agonists or antagonist may be useful in specifically regulating the growth and/or development of pancreatic, gastro-intestinal or thymic-derived cells in culture. These compounds are useful as research reagents for characterizing sites of ligand-receptor interaction. *In vivo*, receptor agonists or antagonists may find application in the treatment pancreatic, gastro-intestinal or thymic diseases.

Agonists or antagonists to Zcytor11 may include small families of peptides. These peptides may be identified employing affinity selection conditions that are known in the art, from a population of candidates present in a peptide library. Peptide libraries include combinatorial libraries chemically synthesized and presented on solid support [Lam et al., *Nature* 354: 82-84 (1991)] or are in solution [Houghten et al., *BioTechniques* 13: 412-

421, (1992)], expressed then linked to plasmid DNA [Cull  
et al., *Proc. Natl. Acad. Sci. USA* 89: 1865-1869 (1992)]  
or expressed and subsequently displayed on the surfaces of  
viruses or cells [Boder and Wittrup, *Nature Biotechnology*  
5 15: 553-557(1997); Cwirla et al. *Science* 276: 1696-1699  
(1997)].

Zcytor11 may also be used within diagnostic  
systems for the detection of circulating levels of ligand.  
10 Within a related embodiment, antibodies or other agents  
that specifically bind to Zcytor11 can be used to detect  
circulating receptor polypeptides. Elevated or depressed  
levels of ligand or receptor polypeptides may be  
indicative of pathological conditions, including cancer.

15  
Zcytor11 receptor polypeptides can be prepared  
by expressing a truncated DNA encoding the extracellular  
domain, for example, a polypeptide which contains residues  
18 through 228 of a human Zcytor11 receptor (SEQ ID NO:2  
20 or the corresponding region of a non-human receptor. It  
is preferred that the extracellular domain polypeptides be  
prepared in a form substantially free of transmembrane and  
intracellular polypeptide segments. For example, the C-  
terminus of the receptor polypeptide may be at residue 228  
25 of SEQ ID NO:2 or the corresponding region of an allelic  
variant or a non-human receptor. To direct the export of  
the receptor domain from the host cell, the receptor DNA  
is linked to a second DNA segment encoding a secretory  
peptide, such as a t-PA secretory peptide. To facilitate  
30 purification of the secreted receptor domain, a C-terminal  
extension, such as a poly-histidine tag, substance P, Flag  
™ peptide [Hopp et al., *Biotechnology* 6:1204-1210, (1988);  
available from Eastman Kodak Co., New Haven, CT] or  
another polypeptide or protein for which an antibody or  
35 other specific binding agent is available, can be fused to  
the receptor polypeptide.



In an alternative approach, a receptor extracellular domain can be expressed as a fusion with immunoglobulin heavy chain constant regions, typically an F<sub>C</sub> fragment, which contains two constant region domains and a hinge region but lacks the variable region. Such fusions are typically secreted as multimeric molecules wherein the Fc portions are disulfide bonded to each other and two receptor polypeptides are arrayed in closed proximity to each other. Fusions of this type can be used to affinity purify the cognate ligand from solution, as an *in vitro* assay tool, to block signals *in vitro* by specifically titrating out ligand, and as antagonists *in vivo* by administering them parenterally to bind circulating ligand and clear it from the circulation. To purify ligand, a Zcytor11-Ig chimera is added to a sample containing the ligand (e.g., cell-conditioned culture media or tissue extracts) under conditions that facilitate receptor-ligand binding (typically near-physiological temperature, pH, and ionic strength). The chimera-ligand complex is then separated by the mixture using protein A, which is immobilized on a solid support (e.g., insoluble resin beads). The ligand is then eluted using conventional chemical techniques, such as with a salt or pH gradient. In the alternative, the chimera itself can be bound to a solid support, with binding and elution carried out as above. The chimeras may be used *in vivo* to regulate gastrointestinal, pancreatic or thymic functions. Chimeras with high binding affinity are administered parenterally (e.g., by intramuscular, subcutaneous or intravenous injection). Circulating molecules bind ligand and are cleared from circulation by normal physiological processes. For use in assays, the chimeras are bound to a support via the F<sub>C</sub> region and used in an ELISA format.

A preferred assay system employing a ligand-binding receptor fragment uses a commercially available biosensor instrument (BIAcore™, Pharmacia Biosensor, Piscataway, NJ), wherein the receptor fragment is  
5 immobilized onto the surface of a receptor chip. Use of this instrument is disclosed by Karlsson, *J. Immunol. Methods* 145:229-240, (1991) and Cunningham and Wells, *J. Mol. Biol.* 234:554-563, (1993). A receptor fragment is covalently attached, using amine or sulfhydryl chemistry,  
10 to dextran fibers that are attached to gold film within the flow cell. A test sample is passed through the cell. If ligand is present in the sample, it will bind to the immobilized receptor polypeptide, causing a change in the refractive index of the medium, which is detected as a  
15 change in surface plasmon resonance of the gold film. This system allows the determination of on- and off-rates, from which binding affinity can be calculated, and assessment of stoichiometry of binding.

20 Ligand-binding receptor polypeptides can also be used within other assay systems known in the art. Such systems include Scatchard analysis for determination of binding affinity. See, Scatchard, *Ann. NY Acad. Sci.* 51: 660-672, (1949) and calorimetric assays [Cunningham et  
25 al., *Science* 253:545-548, (1991); Cunningham et al., *Science* 254:821-825, (1991)].

A receptor ligand-binding polypeptide can also be used for purification of ligand. The receptor  
30 polypeptide is immobilized on a solid support, such as beads of agarose, cross-linked agarose, glass, cellulosic resins, silica-based resins, polystyrene, cross-linked polyacrylamide, or like materials that are stable under the conditions of use. Methods for linking polypeptides  
35 to solid supports are known in the art, and include amine chemistry, cyanogen bromide activation, N-

hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, and hydrazide activation. The resulting media will generally be configured in the form of a column, and fluids containing ligand are passed  
5 through the column one or more times to allow ligand to bind to the receptor polypeptide. The ligand is then eluted using changes in salt concentration or pH to disrupt ligand-receptor binding.

10           Zcytor11 polypeptides can also be used to prepare antibodies that specifically bind to Zcytor11 polypeptides. As used herein, the term "antibodies" includes polyclonal antibodies, monoclonal antibodies, single-chain antibodies and antigen-binding fragments  
15 thereof such as F(ab')<sub>2</sub> and Fab fragments, and the like, including genetically engineered antibodies. Antibodies are defined to be specifically binding if they bind to a Zcytor11 polypeptide with a K<sub>a</sub> of greater than or equal to 10<sup>7</sup>/M. The affinity of a monoclonal antibody can be  
20 readily determined by one of ordinary skill in the art (see, for example, Scatchard, *ibid.*).

          Methods for preparing polyclonal and monoclonal antibodies are well known in the art. See for example,  
25 Sambrook et al., *Molecular Cloning: A Laboratory Manual, Second Edition*, Cold Spring Harbor, NY, (1989); and Hurrell, J. G. R., Ed., *Monoclonal Hybridoma Antibodies: Techniques and Applications*, CRC Press, Inc., Boca Raton, FL, (1982), which are incorporated herein by reference.  
30 As would be evident to one of ordinary skill in the art, polyclonal antibodies can be generated from a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, and rats. The immunogenicity of a Zcytor11 polypeptide may be increased  
35 through the use of an adjuvant such as Freund's complete or incomplete adjuvant. A variety of assays known to

those skilled in the art can be utilized to detect antibodies which specifically bind to Zcytor11 polypeptides. Exemplary assays are described in detail in *Antibodies: A Laboratory Manual*, Harlow and Lane (Eds.), Cold Spring Harbor Laboratory Press, (1988). Representative examples of such assays include: concurrent immunoelectrophoresis, radio-immunoassays, radio-immunoprecipitations, enzyme-linked immunosorbent assays (ELISA), dot blot assays, inhibition or competition assays, and sandwich assays.

Antibodies to Zcytor11 may be used for tagging cells that express the receptor, for affinity purification, within diagnostic assays for determining circulating levels of soluble receptor polypeptides, and as antagonists to block ligand binding and signal transduction *in vitro* and *in vivo*.

Anti-idiotypic antibodies which bind to the antigenic binding site of antibodies to Zcytor11 are also considered part of the present invention. The antigenic binding region of the anti-idiotypic antibody thus will mimic the ligand binding region of Zcytor11. An anti-idiotypic antibody thus could be used to screen for possible ligands of the Zcytor11 receptor. Thus neutralizing antibodies to Zcytor11 can be used to produce anti-idiotypic antibodies by methods well known in the art as is described in, for example, Sambrook et al., *Molecular Cloning: A Laboratory Manual, Second Edition*, (Cold Spring Harbor, NY, 1989); and Hurrell, J. G. R., Ed., *Monoclonal Hybridoma Antibodies: Techniques and Applications*, (CRC Press, Inc., Boca Raton, FL, 1982).

Zcytor11 maps 84.62 cR from the top of the human chromosome a linkage group on the WICGR radiation hybrid

map. The use of surrounding markers positioned Zcytor11 in the 1p35.2 to 35.1 region.

Thus Zcytor11 could be used to generate a probe that  
5 could allow detection of an aberration of the Zcytor11  
gene in the 1p chromosome which may indicate the presence  
of a cancerous cells or a predisposition to cancerous cell  
development. This region of chromosome 1 is frequently  
involved in visible deletions or loss of heterozygosity in  
10 tumors derived from the neural crest cells particularly  
neuroblastomas and melanomas. For further discussions on  
developing polynucleotide probes and hybridization see  
*Current Protocols in Molecular Biology* Ausubel, F. et al.  
Eds. (John Wiley & Sons Inc. 1991).

15

The invention is further illustrated by the following non-limiting examples.

Example 1Production a Pancreatic Islet Cell cDNA Library

Zcytor11 was cloned from a pancreatic islet cell  
5 cDNA library produced according to the following  
procedure. RNA extracted from pancreatic islet cells was  
reversed transcribed in the following manner. The first  
strand cDNA reaction contained 10 µl of human pancreatic  
islet cell poly d(T)-selected poly (A)<sup>+</sup> mRNA (Clontech,  
10 Palo Alto, CA) at a concentration of 1.0 mg/ml, and 2 µl  
of 20 pmole/µl first strand primer ZC6171 (SEQ ID NO: 6)  
containing an Xho I restriction site. The mixture was  
heated at 70°C for 2.5 minutes and cooled by chilling on  
ice. First strand cDNA synthesis was initiated by the  
15 addition of 8 µl of first strand buffer (5x SUPERScript®  
buffer; Life Technologies, Gaithersburg, MD), 4 µl of 100  
mM dithiothreitol, and 3 µl of a deoxynucleotide  
triphosphate (dNTP) solution containing 10 mM each of  
dTTP, dATP, dGTP and 5-methyl-dCTP (Pharmacia LKB  
20 Biotechnology, Piscataway, NJ) to the RNA-primer mixture.  
The reaction mixture was incubated at 40° C for 2 minutes,  
followed by the addition of 10 µl of 200 U/µl RNase H<sup>-</sup>  
reverse transcriptase (SUPERScript II®; Life  
Technologies). The efficiency of the first strand  
25 synthesis was analyzed in a parallel reaction by the  
addition of 10 µCi of <sup>32</sup>P-αdCTP to a 5 µl aliquot from one  
of the reaction mixtures to label the reaction for  
analysis. The reactions were incubated at 40°C for 5  
minutes, 45°C for 50 minutes, then incubated at 50°C for 10  
30 minutes. Unincorporated <sup>32</sup>P-αdCTP in the labeled reaction  
was removed by chromatography on a 400 pore size gel  
filtration column (Clontech Laboratories, Palo Alto, CA).  
The unincorporated nucleotides and primers in the  
unlabeled first strand reactions were removed by  
35 chromatography on 400 pore size gel filtration column  
(Clontech Laboratories, Palo Alto, CA). The length of

labeled first strand cDNA was determined by agarose gel electrophoresis.

The second strand reaction contained 102  $\mu$ l of  
5 the unlabeled first strand cDNA, 30  $\mu$ l of 5x polymerase I  
buffer (125 mM Tris: HCl, pH 7.5, 500 mM KCl, 25 mM MgCl<sub>2</sub>,  
50mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>), 2.0  $\mu$ l of 100 mM dithiothreitol, 3.0  $\mu$ l  
of a solution containing 10 mM of each deoxynucleotide  
triphosphate, 7  $\mu$ l of 5 mM  $\beta$ -NAD, 2.0  $\mu$ l of 10 U/ $\mu$ l *E.*  
10 *coli* DNA ligase (New England Biolabs; Beverly, MA), 5  $\mu$ l  
of 10 U/ $\mu$ l *E. coli* DNA polymerase I (New England Biolabs,  
Beverly, MA), and 1.5  $\mu$ l of 2 U/ $\mu$ l RNase H (Life  
Technologies, Gaithersburg, MD). A 10  $\mu$ l aliquot from one  
of the second strand synthesis reactions was labeled by  
15 the addition of 10  $\mu$ Ci <sup>32</sup>P- $\alpha$ dCTP to monitor the  
efficiency of second strand synthesis. The reactions were  
incubated at 16° C for two hours, followed by the addition  
of 1  $\mu$ l of a 10 mM dNTP solution and 6.0  $\mu$ l T4 DNA  
polymerase (10 U/ $\mu$ l, Boehringer Mannheim, Indianapolis,  
20 IN) and incubated for an additional 10 minutes at 16°C.  
Unincorporated <sup>32</sup>P- $\alpha$ dCTP in the labeled reaction was  
removed by chromatography through a 400 pore size gel  
filtration column (Clontech Laboratories, Palo Alto, CA)  
before analysis by agarose gel electrophoresis. The  
25 reaction was terminated by the addition of 10.0  $\mu$ l 0.5 M  
EDTA and extraction with phenol/chloroform and chloroform  
followed by ethanol precipitation in the presence of 3.0 M  
Na acetate and 2  $\mu$ l of Pellet Paint carrier (Novagen,  
Madison, WI). The yield of cDNA was estimated to be  
30 approximately 2  $\mu$ g from starting mRNA template of 10  $\mu$ g.

*Eco* RI adapters were ligated onto the 5' ends of  
the cDNA described above to enable cloning into an  
expression vector. A 12.5  $\mu$ l aliquot of cDNA (~2.0  $\mu$ g)  
35 and 3  $\mu$ l of 69 pmole/ $\mu$ l of *Eco* RI adapter (Pharmacia LKB  
Biotechnology Inc., Piscataway, NJ) were mixed with 2.5  $\mu$ l

10x ligase buffer (660 mM Tris-HCl pH 7.5, 100 mM MgCl<sub>2</sub>),  
2.5 µl of 10 mM ATP, 3.5 µl 0.1 M DTT and 1 µl of 15 U/µl  
T4 DNA ligase (Promega Corp., Madison, WI). The reaction  
was incubated 1 hour at 5°C, 2 hours at 7.5°C, 2 hours at  
5 10°C, 2 hours at 12.5°C and 16 hours at 10° C. The  
reaction was terminated by the addition of 65 µl H<sub>2</sub>O and 10  
µl 10X H buffer (Boehringer Mannheim, Indianapolis, IN)  
and incubation at 70°C for 20 minutes.

10 To facilitate the directional cloning of the  
cDNA into an expression vector, the cDNA was digested with  
*Xho* I, resulting in a cDNA having a 5' *Eco* RI cohesive end  
and a 3' *Xho* I cohesive end. The *Xho* I restriction site  
at the 3' end of the cDNA had been previously introduced.  
15 Restriction enzyme digestion was carried out in a reaction  
mixture by the addition of 1.0 µl of 40 U/µl *Xho* I  
(Boehringer Mannheim, Indianapolis, IN). Digestion was  
carried out at 37°C for 45 minutes. The reaction was  
terminated by incubation at 70°C for 20 minutes and  
20 chromatography through a 400 pore size gel filtration  
column (Clontech Laboratories, Palo Alto, CA).

The cDNA was ethanol precipitated, washed with  
70% ethanol, air dried and resuspended in 10.0 µl water, 2  
25 µl of 10X kinase buffer (660 mM Tris-HCl, pH 7.5, 100 mM  
MgCl<sub>2</sub>), 0.5 µl 0.1 M DTT, 2 µl 10 mM ATP, 2 µl T4  
polynucleotide kinase (10 U/µl, Life Technologies,  
Gaithersburg, MD). Following incubation at 37° C for 30  
minutes, the cDNA was ethanol precipitated in the presence  
30 of 2.5 M Ammonium Acetate, and electrophoresed on a 0.8%  
low melt agarose gel. The contaminating adapters and cDNA  
below 0.6 Kb in length were excised from the gel. The  
electrodes were reversed, and the cDNA was electrophoresed  
until concentrated near the lane origin. The area of the  
35 gel containing the concentrated cDNA was excised and  
placed in a microfuge tube, and the approximate volume of



the gel slice was determined. An aliquot of water approximately three times the volume of the gel slice (300  $\mu$ l) and 35  $\mu$ l 10x  $\beta$ -agarose I buffer (New England Biolabs) was added to the tube, and the agarose was melted by heating to 65°C for 15 minutes. Following equilibration of the sample to 45°C, 3  $\mu$ l of 1 U/ $\mu$ l  $\beta$ -agarose I (New England Biolabs, Beverly, MA) was added, and the mixture was incubated for 60 minutes at 45°C to digest the agarose. After incubation, 40  $\mu$ l of 3 M Na acetate was added to the sample, and the mixture was incubated on ice for 15 minutes. The sample was centrifuged at 14,000 x g for 15 minutes at room temperature to remove undigested agarose. The cDNA was ethanol precipitated, washed in 70% ethanol, air-dried and resuspended in 40  $\mu$ l water.

Following recovery from low-melt agarose gel, the cDNA was cloned into the Eco RI and Xho I sites of pBLUESCRIPT SK+ vector (Gibco/BRL, Gaithersburg, MD) and electroporated into DH10B cells. Bacterial colonies containing ESTs of known genes were identified and eliminated from sequence analysis by reiterative cycles of probe hybridization to hi-density colony filter arrays (Genome Systems, St. Louis, MI). cDNAs of known genes were pooled in groups of 50 - 100 inserts and were labeled with  $^{32}$ P- $\alpha$ dCTP using a MEGAPRIME labeling kit (Amersham, Arlington Heights, IL). Colonies which did not hybridize to the probe mixture were selected for sequencing. Sequencing was done using an ABI 377 sequencer using either the T3 or the reverse primer. The resulting data were analyzed which resulted in the identification of EST LISF104376 (SEQ ID NO: 3).

Example 2.Cloning of Zcytor11

5                   Expressed sequence tag (EST) LISF104376 (SEQ ID NO:3) contained in plasmid pSLIS4376 was isolated from a human pancreatic islet cell cDNA library. Following sequencing of the entire pSLIS4376 cDNA insert, it was determined not to encode a full-length Zcytor11  
10 polypeptide.

                  A full length Zcytor11 encoding cDNA was isolated by screening a human islet cDNA library using a probe that was generated by PCR primers ZC14,295 (SEQ ID  
15 NO:4) and ZC14294 (SEQ ID NO:5) and the pSLIS4376 template. (For details on the construction of the pancreatic islet cell cDNA library, see Example 2 below.) The resulting probe of 276 bp containing nucleotides 142 to 417 of SEQ ID NO:1 was purified by chromatography  
20 through a 100 pore size spin column (Clontech, Palo Alto, CA). The purified probe was labeled with <sup>32</sup>P-αCTP using a MEGAPRIME® labeling kit (Amersham Corp., Arlington Heights, IL). The labeled probe was purified on a NUCTRAP® purification column (Stratagene Cloning Systems, La Jolla,  
25 CA) for library screening.

                  Following recovery of the islet cDNA from a low-melt agarose gel from Example 1, the cDNA was cloned into the Eco RI and Xho I sites; of pBLUESCRIPT SK+ (Gibco/BRL,  
30 Gaithersburg, MD) and electroporated into DH10B cells. Bacterial clones from resulting cDNA library were individually placed on a grid of a high-density colony filter arrays (Genome Systems, St. Louis, MI) and were probed with the labeled Zcytor11 probe described above. A  
35 glycerol stock of each clone on each grid was also made to expedite the isolation of positive clones. The filters were first pre-washed in an aqueous solution containing

0.25X standard sodium citrate (SSC), 0.25% sodium dodecyl sulfate (SDS) and 1 mM EDTA to remove cellular debris and then prehybridized in a hybridization solution (5X SSC, 5X Denhardt's solution, 0.2% SDS and 1 mM EDTA) containing  
5 100 µg/ml heat-denature, sheared salmon sperm DNA).

Fifty nanograms of the PCR-derived Zcytor11 probe was radiolabeled with 32P-αdCTP by random priming using the MEGAPRIME® DNA labeling system (Amersham,  
10 Arlington Heights, IL). The prehybridization solution was replaced with fresh hybridization containing  $1 \times 10^6$  cpm/ml probe and allowed to hybridize at 65° C overnight. The filters were washed in a wash buffer containing 0.25X SSC, 0.25% SDS and 1 mM EDTA at 65° C.

15  
Following autoradiography, three signals were detected among 40,000 clones on the grids of the filter array. From the grid coordinates of the positive signals, the corresponding clones, pSLR11-1, pSLR11-2 and pSLR11-3  
20 were retrieved from the glycerol stock and their inserts sequenced. The insert in pSLR11-1 was determined to be 2831 base pairs (bp) and encoded full-length Zcytor11 polypeptide.

25 Example 3

Expression of Human Zcytor11 mRNA in Human Tissues

Poly(A)<sup>+</sup> RNAs isolated brain, colon, heart, kidney,  
30 liver, lung, ovary, pancreas, prostate, placenta, peripheral blood leukocytes, stomach, spleen, skeletal muscle, small intestine, testis, thymus, thyroid, spinal cord, lymph node, trachea, adrenal gland and bone marrow were hybridized under high stringency conditions with a  
35 radiolabeled DNA probe containing nucleotides 181-456 of (SEQ ID NO:1). Membranes were purchased from Clontech. The

membrane were washed with 0.1X SSC, 0.1% SDS at 50°C and  
autoradiographed for 24 hours. The mRNA levels were  
highest in pancreas with low levels in colon, small  
intestine and thymus. The receptor mRNA localization  
5 suggests that Zcytor11 may regulate gastrointestinal,  
pancreatic or thymic functions.

#### Example 4

##### 10        Chromosomal Assignment and Placement of Zcytor11

Zcytor11 was mapped to chromosome 1 using the  
commercially available version of the Whitehead  
Institute/MIT Center for Genome Research's "GeneBridge 4  
15 Radiation Hybrid Panel" (Research Genetics, Inc.,  
Huntsville, AL). The GeneBridge 4 Radiation Hybrid Panel  
contains PCRable DNAs from each of 93 radiation hybrid  
clones, plus two control DNAs (the HFL donor and the A23  
recipient). A publicly available WWW server ([http://www-](http://www-genome.wi.mit.edu/cgi-bin/contig/rhmapper.pl)  
20 [genome.wi.mit.edu/cgi-bin/contig/rhmapper.pl](http://www-genome.wi.mit.edu/cgi-bin/contig/rhmapper.pl)) allows  
mapping relative to the Whitehead Institute/MIT Center for  
Genome Research's radiation hybrid map of the human genome  
(the "WICGR" radiation hybrid map) which was constructed  
with the GeneBridge 4 Radiation Hybrid Panel.

25

## CLAIMS

We claim:

1. An isolated polynucleotide encoding a ligand-binding receptor polypeptide, said polypeptide being defined by amino acid residues 18 to 228 of SEQ ID NO:2.
2. An isolated polynucleotide according to claim 1 wherein said polypeptide further comprises a transmembrane domain.
3. An isolated polynucleotide according to claim 2 wherein said transmembrane domain comprises residues 229 to 251 of SEQ ID NO:2.
4. An isolated polynucleotide according to claim 2 wherein said polypeptide further comprises an intracellular domain.
5. An isolated polynucleotide according to claim 4 wherein said intracellular domain comprises residues 252 to 574 of SEQ ID NO:2.
6. An isolated polynucleotide according to claim 1 which is a DNA as shown in SEQ ID NO:1 from nucleotide 34 to nucleotide 1755.
7. An isolated polynucleotide according to claim 1 wherein said polypeptide further comprises an affinity tag.
8. An isolated polynucleotide according to claim 7 wherein said affinity tag is polyhistidine, protein A, glutathione S transferase, substance P, or an immunoglobulin heavy chain constant region.
9. An isolated polynucleotide according to claim 1 wherein said polynucleotide is DNA.

10. An isolated polynucleotide encoding a polypeptide selected from a group defined SEQ ID NO:2 consisting of residues 1 to 228, residues 1 to 251, residues 1 to 574, residues 2 to 228, residues 2 to 251, residues 2 to 574, residues 229 to 251, residues 229 to 574 and residues 252 to 574.

11. An expression vector comprising the following operably linked elements:  
a transcription promoter;  
a DNA segment encoding a ligand-binding receptor polypeptide, said polypeptide being defined by amino residues 18 to 228 of SEQ ID NO:2; and  
a transcription terminator.

12. An expression vector according to claim 11 wherein said polypeptide further comprises a signal sequence.

13. An expression vector according to claim 11 wherein said polypeptide further comprises a transmembrane domain.

14. An expression vector according to claim 11 wherein said transmembrane domain comprises residues 229 to 251 of SEQ ID NO:2.

15. An expression vector according to claim 13 wherein said polypeptide further comprises an intracellular domain.

16. An expression vector according to claim 15 wherein said intracellular domain comprises residues 252 to 574 of SEQ ID NO:2.

17. An expression vector according to claim 11 wherein further comprising a DNA sequence encoding an affinity tag.

18. An expression vector according to claim 17 wherein the affinity tag is an immunoglobulin F<sub>C</sub> polypeptide.

19. A transformed or transfected cell into which has been introduced an expression vector according to claim 11, wherein said cell expresses a receptor polypeptide encoded by the DNA segment.

20. An isolated polypeptide defined by residues 18-228 of SEQ ID NO: 2.

21. The isolated polypeptide of claim 20 further containing either a sequence which defines a transmembrane domain or a sequence which defines an intracellular domain or both.

22. The isolated polypeptide of claim 23 wherein the transmembrane domain is defined by amino acid residues 229-251 of SEQ ID NO: 2 and the intracellular domain is defined by amino acid residues 252-574 of SEQ ID NO:2.

23. An isolated polypeptide according to claim 20 further containing a sequence which defines an affinity tag.

24. A method for detecting a ligand within a test sample, comprising contacting a test sample with a polypeptide comprising residues 18 to 228 of SEQ ID NO:2; and detecting binding of said polypeptide to a ligand in the sample.

25. An antibody that specifically binds to a polypeptide of claim 20.

26. An anti-idiotypic antibody which binds to an antigenic binding site of an antibody of claim 25.

27. An isolated polypeptide selected from the group consisting of residues 1 to 228, residues 1 to 251, residues 1 to 574 residues 2 to 228, residues 2 to 551, and residues 2 to 574 of SEQ ID NO: 2.



## SEQUENCE LISTING

## (1) GENERAL INFORMATION

- (i) APPLICANT: ZymoGenetics, Inc.
- (ii) TITLE OF THE INVENTION: MAMMALIAN CYTOKINE RECEPTOR - 11
- (iii) NUMBER OF SEQUENCES: 11
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Zymogenetics
  - (B) STREET: 1201 Eastlake Ave East
  - (C) CITY: Seattle
  - (D) STATE: WA
  - (E) COUNTRY: USA
  - (F) ZIP: 98102
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Diskette
  - (B) COMPUTER: IBM Compatible
  - (C) OPERATING SYSTEM: DOS
  - (D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: 08/906,713
  - (B) FILING DATE: 05-AUG-1997
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Lunn, Paul G
  - (B) REGISTRATION NUMBER: 32,743
  - (C) REFERENCE/DOCKET NUMBER: 97-52PC
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: 206-442-6627
  - (B) TELEFAX: 206-442-6678
  - (C) TELEX:

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2831 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
- (B) LOCATION: 34...1755
- (D) OTHER INFORMATION:

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TAGAGGCCAA GGGAGGGCTC TGTGCCAGCC CCG ATG AGG ACG CTG CTG ACC ATC	54
Met Arg Thr Leu Leu Thr Ile	
1 5	
TTG ACT GTG GGA TCC CTG GCT GCT CAC GCC CCT GAG GAC CCC TCG GAT	102
Leu Thr Val Gly Ser Leu Ala Ala His Ala Pro Glu Asp Pro Ser Asp	
10 15 20	
CTG CTC CAG CAC GTG AAA TTC CAG TCC AGC AAC TTT GAA AAC ATC CTG	150
Leu Leu Gln His Val Lys Phe Gln Ser Ser Asn Phe Glu Asn Ile Leu	
25 30 35	
ACG TGG GAC AGC GGG CCA GAG GGC ACC CCA GAC ACG GTC TAC AGC ATC	198
Thr Trp Asp Ser Gly Pro Glu Gly Thr Pro Asp Thr Val Tyr Ser Ile	
40 45 50 55	
GAG TAT AAG ACG TAC GGA GAG AGG GAC TGG GTG GCA AAG AAG GGC TGT	246
Glu Tyr Lys Thr Tyr Gly Glu Arg Asp Trp Val Ala Lys Lys Gly Cys	
60 65 70	
CAG CGG ATC ACC CGG AAG TCC TGC AAC CTG ACG GTG GAG ACG GGC AAC	294
Gln Arg Ile Thr Arg Lys Ser Cys Asn Leu Thr Val Glu Thr Gly Asn	
75 80 85	
CTC ACG GAG CTC TAC TAT GCC AGG GTC ACC GCT GTC AGT GCG GGA GGC	342
Leu Thr Glu Leu Tyr Tyr Ala Arg Val Thr Ala Val Ser Ala Gly Gly	
90 95 100	

CGG TCA GCC ACC AAG ATG ACT GAC AGG TTC AGC TCT CTG CAG CAC ACT	390
Arg Ser Ala Thr Lys Met Thr Asp Arg Phe Ser Ser Leu Gln His Thr	
105 110 115	
ACC CTC AAG CCA CCT GAT GTG ACC TGT ATC TCC AAA GTG AGA TCG ATT	438
Thr Leu Lys Pro Pro Asp Val Thr Cys Ile Ser Lys Val Arg Ser Ile	
120 125 130 135	
CAG ATG ATT GTT CAT CCT ACC CCC ACG CCA ATC CGT GCA GGC GAT GGC	486
Gln Met Ile Val His Pro Thr Pro Thr Pro Ile Arg Ala Gly Asp Gly	
140 145 150	
CAC CGG CTA ACC CTG GAA GAC ATC TTC CAT GAC CTG TTC TAC CAC TTA	534
His Arg Leu Thr Leu Glu Asp Ile Phe His Asp Leu Phe Tyr His Leu	
155 160 165	
GAG CTC CAG GTC AAC CGC ACC TAC CAA ATG CAC CTT GGA GGG AAG CAG	582
Glu Leu Gln Val Asn Arg Thr Tyr Gln Met His Leu Gly Gly Lys Gln	
170 175 180	
AGA GAA TAT GAG TTC TTC GGC CTG ACC CCT GAC ACA GAG TTC CTT GGC	630
Arg Glu Tyr Glu Phe Phe Gly Leu Thr Pro Asp Thr Glu Phe Leu Gly	
185 190 195	
ACC ATC ATG ATT TGC GTT CCC ACC TGG GCC AAG GAG AGT GCC CCC TAC	678
Thr Ile Met Ile Cys Val Pro Thr Trp Ala Lys Glu Ser Ala Pro Tyr	
200 205 210 215	
ATG TGC CGA GTG AAG ACA CTG CCA GAC CGG ACA TGG ACC TAC TCC TTC	726
Met Cys Arg Val Lys Thr Leu Pro Asp Arg Thr Trp Thr Tyr Ser Phe	
220 225 230	
TCC GGA GCC TTC CTG TTC TCC ATG GGC TTC CTC GTC GCA GTA CTC TGC	774
Ser Gly Ala Phe Leu Phe Ser Met Gly Phe Leu Val Ala Val Leu Cys	
235 240 245	
TAC CTG AGC TAC AGA TAT GTC ACC AAG CCG CCT GCA CCT CCC AAC TCC	822
Tyr Leu Ser Tyr Arg Tyr Val Thr Lys Pro Pro Ala Pro Pro Asn Ser	
250 255 260	
CTG AAC GTC CAG CGA GTC CTG ACT TTC CAG CCG CTG CGC TTC ATC CAG	870
Leu Asn Val Gln Arg Val Leu Thr Phe Gln Pro Leu Arg Phe Ile Gln	
265 270 275	

GAG CAC GTC CTG ATC CCT GTC TTT GAC CTC AGC GGC CCC AGC AGT CTG Glu His Val Leu Ile Pro Val Phe Asp Leu Ser Gly Pro Ser Ser Leu 280 285 290 295	918
GCC CAG CCT GTC CAG TAC TCC CAG ATC AGG GTG TCT GGA CCC AGG GAG Ala Gln Pro Val Gln Tyr Ser Gln Ile Arg Val Ser Gly Pro Arg Glu 300 305 310	966
CCC GCA GGA GCT CCA CAG CGG CAT AGC CTG TCC GAG ATC ACC TAC TTA Pro Ala Gly Ala Pro Gln Arg His Ser Leu Ser Glu Ile Thr Tyr Leu 315 320 325	1014
GGG CAG CCA GAC ATC TCC ATC CTC CAG CCC TCC AAC GTG CCA CCT CCC Gly Gln Pro Asp Ile Ser Ile Leu Gln Pro Ser Asn Val Pro Pro Pro 330 335 340	1062
CAG ATC CTC TCC CCA CTG TCC TAT GCC CCA AAC GCT GCC CCT GAG GTC Gln Ile Leu Ser Pro Leu Ser Tyr Ala Pro Asn Ala Ala Pro Glu Val 345 350 355	1110
GGG CCC CCA TCC TAT GCA CCT CAG GTG ACC CCC GAA GCT CAA TTC CCA Gly Pro Pro Ser Tyr Ala Pro Gln Val Thr Pro Glu Ala Gln Phe Pro 360 365 370 375	1158
TTC TAC GCC CCA CAG GCC ATC TCT AAG GTC CAG CCT TCC TCC TAT GCC Phe Tyr Ala Pro Gln Ala Ile Ser Lys Val Gln Pro Ser Ser Tyr Ala 380 385 390	1206
CCT CAA GCC ACT CCG GAC AGC TGG CCT CCC TCC TAT GGG GTA TGC ATG Pro Gln Ala Thr Pro Asp Ser Trp Pro Pro Ser Tyr Gly Val Cys Met 395 400 405	1254
GAA GGT TCT GGC AAA GAC TCC CCC ACT GGG ACA CTT TCT AGT CCT AAA Glu Gly Ser Gly Lys Asp Ser Pro Thr Gly Thr Leu Ser Ser Pro Lys 410 415 420	1302
CAC CTT AGG CCT AAA GGT CAG CTT CAG AAA GAG CCA CCA GCT GGA AGC His Leu Arg Pro Lys Gly Gln Leu Gln Lys Glu Pro Pro Ala Gly Ser 425 430 435	1350
TGC ATG TTA GGT GGC CTT TCT CTG CAG GAG GTG ACC TCC TTG GCT ATG Cys Met Leu Gly Gly Leu Ser Leu Gln Glu Val Thr Ser Leu Ala Met 440 445 450 455	1398

ACA GAC AGA ACA TCT GAC CCA AAT GTG CTA CAC AGT GGG GAG GAA GGG 1494  
Thr Asp Arg Thr Ser Asp Pro Asn Val Leu His Ser Gly Glu Glu Gly  
475 480 485

ACA CCA CAG TAC CTA AAG GGC CAG CTC CCC CTC CTC TCC TCA GTC CAG 1542  
Thr Pro Gln Tyr Leu Lys Gly Gln Leu Pro Leu Leu Ser Ser Val Gln  
490 495 500

ATC GAG GGC CAC CCC ATG TCC CTC CCT TTG CAA CCT CCT TCC GGT CCA 1590  
Ile Glu Gly His Pro Met Ser Leu Pro Leu Gln Pro Pro Ser Gly Pro  
505 510 515

TGT TCC CCC TCG GAC CAA GGT CCA AGT CCC TGG GGC CTG CTG GAG TCC 1638  
Cys Ser Pro Ser Asp Gln Gly Pro Ser Pro Trp Gly Leu Leu Glu Ser  
520 525 530 535

CTT GTG TGT CCC AAG GAT GAA GCC AAG AGC CCA GCC CCT GAG ACC TCA 1686  
Leu Val Cys Pro Lys Asp Glu Ala Lys Ser Pro Ala Pro Glu Thr Ser  
540 545 550

GAC CTG GAG CAG CCC ACA GAA CTG GAT TCT CTT TTC AGA GGC CTG GCC 1734  
Asp Leu Glu Gln Pro Thr Glu Leu Asp Ser Leu Phe Arg Gly Leu Ala  
555 560 565

CTG ACT GTG CAG TGG GAG TCC TGAGGGGAAT GGGAAAGGCT TGGTGCTTCC TCCC 1789  
Leu Thr Val Gln Trp Glu Ser  
570

TGTCCTACC	CAGTGTACA	TCCTTGGCTG	TCAATCCCAT	GCCTGCCCAT	GCCACACACT	1849
CTGCGATCTG	GCCTCAGACG	GGTGCCCTTG	AGAGAAGCAG	AGGGAGTGGC	ATGCAGGGCC	1909
CCTGCCATGG	GTGCGCTCCT	CACCGGAACA	AAGCAGCATG	ATAAGGACTG	CAGCGGGGGA	1969
GCTCTGGGGA	GCAGCTTGTG	TAGACAAGCG	CGTGCTCGCT	GAGCCCTGCA	AGGCAGAAAT	2029
GACAGTGCAA	GGAGGAAATG	CAGGGAAACT	CCCGAGGTCC	AGAGCCCCAC	CTCCTAACAC	2089
CATGGATTCA	AAGTGCTCAG	GGAATTTGCC	TCTCCTTGCC	CCATTCTGG	CCAGTTTCAC	2149
AATCTAGCTC	GACAGAGCAT	GAGGCCCTG	CCTCTTCTGT	CATTGTTCAA	AGGTGGGAAG	2209
AGAGCCTGGA	AAAGAACCAG	GCCTGGAAAA	GAACCAGAAG	GAGGCTGGGC	AGAACCAGAA	2269
CAACCTGCAC	TTCTGCCAAG	GCCAGGGCCA	GCAGGACGGC	AGGACTCTAG	GGAGGGGTGT	2329
GGCCTGCAGC	TCATTCCCAG	CCAGGGCAAC	TGCCTGACGT	TGCACGATT	CAGCTTCATT	2389
CCTCTGATAG	AACAAAGCGA	AATGCAGGTC	CACCAGGGAG	GGAGACACAC	AAGCCTTTTC	2449
TGCAGGCAGG	AGTTTCAGAC	CCTATCCTGA	GAATGGGGTT	TGAAAGGAAG	GTGAGGGCTG	2509
TGGCCCCTGG	ACGGGTACAA	TAACACACTG	TACTGATGTC	ACAACTTTGC	AAGCTCTGCC	2569

```

TTGGGTTCAG CCCATCTGGG CTCAAATTCC AGCCTCACCA CTCACAAGCT GTGTGACTTC 2629
AAACAAATGA AATCAGTGCC CAGAACCTCG GTTTCCTCAT CTGTAATGTG GGGATCATAA 2689
CACCTACCTC ATGGAGTTGT GGTGAAGATG AAATGAAGTC ATGTCTTTAA AGTGCTTAAT 2749
AGTGCCTGGT ACATGGGCAG TGCCCAATAA ACGGTAGCTA TTTAAAAAAA AAAAAAAAAA 2809
AAAAAATAG CGGCCGCCTC GA 2831

```

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 574 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

Met Arg Thr Leu Leu Thr Ile Leu Thr Val Gly Ser Leu Ala Ala His
 1             5             10             15
Ala Pro Glu Asp Pro Ser Asp Leu Leu Gln His Val Lys Phe Gln Ser
      20             25             30
Ser Asn Phe Glu Asn Ile Leu Thr Trp Asp Ser Gly Pro Glu Gly Thr
      35             40             45
Pro Asp Thr Val Tyr Ser Ile Glu Tyr Lys Thr Tyr Gly Glu Arg Asp
 50             55             60
Trp Val Ala Lys Lys Gly Cys Gln Arg Ile Thr Arg Lys Ser Cys Asn
65             70             75             80
Leu Thr Val Glu Thr Gly Asn Leu Thr Glu Leu Tyr Tyr Ala Arg Val
      85             90             95
Thr Ala Val Ser Ala Gly Gly Arg Ser Ala Thr Lys Met Thr Asp Arg
      100            105            110
Phe Ser Ser Leu Gln His Thr Thr Leu Lys Pro Pro Asp Val Thr Cys
      115            120            125
Ile Ser Lys Val Arg Ser Ile Gln Met Ile Val His Pro Thr Pro Thr
      130            135            140
Pro Ile Arg Ala Gly Asp Gly His Arg Leu Thr Leu Glu Asp Ile Phe
      145            150            155            160
His Asp Leu Phe Tyr His Leu Glu Leu Gln Val Asn Arg Thr Tyr Gln
      165            170            175
Met His Leu Gly Gly Lys Gln Arg Glu Tyr Glu Phe Phe Gly Leu Thr
      180            185            190
Pro Asp Thr Glu Phe Leu Gly Thr Ile Met Ile Cys Val Pro Thr Trp
      195            200            205

```

Ala Lys Glu Ser Ala Pro Tyr Met Cys Arg Val Lys Thr Leu Pro Asp  
 210 215 220  
 Arg Thr Trp Thr Tyr Ser Phe Ser Gly Ala Phe Leu Phe Ser Met Gly  
 225 230 235 240  
 Phe Leu Val Ala Val Leu Cys Tyr Leu Ser Tyr Arg Tyr Val Thr Lys  
 245 250 255  
 Pro Pro Ala Pro Pro Asn Ser Leu Asn Val Gln Arg Val Leu Thr Phe  
 260 265 270  
 Gln Pro Leu Arg Phe Ile Gln Glu His Val Leu Ile Pro Val Phe Asp  
 275 280 285  
 Leu Ser Gly Pro Ser Ser Leu Ala Gln Pro Val Gln Tyr Ser Gln Ile  
 290 295 300  
 Arg Val Ser Gly Pro Arg Glu Pro Ala Gly Ala Pro Gln Arg His Ser  
 305 310 315 320  
 Leu Ser Glu Ile Thr Tyr Leu Gly Gln Pro Asp Ile Ser Ile Leu Gln  
 325 330 335  
 Pro Ser Asn Val Pro Pro Pro Gln Ile Leu Ser Pro Leu Ser Tyr Ala  
 340 345 350  
 Pro Asn Ala Ala Pro Glu Val Gly Pro Pro Ser Tyr Ala Pro Gln Val  
 355 360 365  
 Thr Pro Glu Ala Gln Phe Pro Phe Tyr Ala Pro Gln Ala Ile Ser Lys  
 370 375 380  
 Val Gln Pro Ser Ser Tyr Ala Pro Gln Ala Thr Pro Asp Ser Trp Pro  
 385 390 395 400  
 Pro Ser Tyr Gly Val Cys Met Glu Gly Ser Gly Lys Asp Ser Pro Thr  
 405 410 415  
 Gly Thr Leu Ser Ser Pro Lys His Leu Arg Pro Lys Gly Gln Leu Gln  
 420 425 430  
 Lys Glu Pro Pro Ala Gly Ser Cys Met Leu Gly Gly Leu Ser Leu Gln  
 435 440 445  
 Glu Val Thr Ser Leu Ala Met Glu Glu Ser Gln Glu Ala Lys Ser Leu  
 450 455 460  
 His Gln Pro Leu Gly Ile Cys Thr Asp Arg Thr Ser Asp Pro Asn Val  
 465 470 475 480  
 Leu His Ser Gly Glu Gly Thr Pro Gln Tyr Leu Lys Gly Gln Leu  
 485 490 495  
 Pro Leu Leu Ser Ser Val Gln Ile Glu Gly His Pro Met Ser Leu Pro  
 500 505 510  
 Leu Gln Pro Pro Ser Gly Pro Cys Ser Pro Ser Asp Gln Gly Pro Ser  
 515 520 525  
 Pro Trp Gly Leu Leu Glu Ser Leu Val Cys Pro Lys Asp Glu Ala Lys  
 530 535 540  
 Ser Pro Ala Pro Glu Thr Ser Asp Leu Glu Gln Pro Thr Glu Leu Asp  
 545 550 555 560

Ser Leu Phe Arg Gly Leu Ala Leu Thr Val Gln Trp Glu Ser  
565 570

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 354 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GCAACTTTGA	AAACATCCTG	ACGTGGGACA	GCGGGCCAGA	GGGCACCCCA	GACACGGTCT	60
ACAGCATCGA	GTATAANACG	TACGGAGAGA	GGGACTGGGT	GGCAAAGAAN	GGCTGTCAGC	120
GGATCACCCG	GAAGTCCTGC	AACCTGACGG	TGGAGACGGG	CAACCTCACG	GAGCTCTACT	180
ATGCCAGGGT	CACCGCTGTC	AGTGCGGGAG	GCCGGTCANC	CACCAAGATG	ACTGACAGGT	240
TCAGCTCTCT	GCAGCACACT	ACCCTCAAGC	CACCTGATGT	GACCTGTATC	TCCAAAGTGA	300
GATCGATTCT	GATGATTGTT	CATCCTACCC	CCACGCCAAT	CCGTGCAGGC	GATG	354

(2) INFORMATION FOR SEQ ID NO:4:

(j) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AACATCCTGA CGTGGGACAG CGGGCCAGAG 30

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: Other



(iv) ANTISENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ACAGGTCACA TCAGGTGGCT TGAGGGTAGT

30

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GTCTGGGTTC GCTACTCGAG GCGGCCGCTA TTTTTTTTTT TTTTTTTT

48

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Ser	Ile	Glu	Tyr	Lys	Thr	Tyr	Gly	Glu	Arg	Asp	Trp	Val	Ala	Lys	Lys
1				5				10						15	
Gly	Cys														

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

His	Pro	Thr	Pro	Thr	Pro	Ile	Arg	Ala	Gly	Asp	Gly	His	Arg	Leu	Thr
1				5					10					15	
Leu	Asp														

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 211 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Pro	Glu	Asp	Pro	Ser	Asp	Leu	Leu	Gln	His	Val	Lys	Phe	Gln	Ser	Ser
1				5				10						15	
Asn	Phe	Glu	Asn	Ile	Leu	Thr	Trp	Asp	Ser	Gly	Pro	Glu	Gly	Thr	Pro
			20					25					30		
Asp	Thr	Val	Tyr	Ser	Ile	Glu	Tyr	Lys	Thr	Tyr	Gly	Glu	Arg	Asp	Trp
		35					40					45			
Val	Ala	Lys	Lys	Gly	Cys	Gln	Arg	Ile	Thr	Arg	Lys	Ser	Cys	Asn	Leu
	50				55					60					
Thr	Val	Glu	Thr	Gly	Asn	Leu	Thr	Glu	Leu	Tyr	Tyr	Ala	Arg	Val	Thr
65					70				75					80	
Ala	Val	Ser	Ala	Gly	Gly	Arg	Ser	Ala	Thr	Lys	Met	Thr	Asp	Arg	Phe
			85					90					95		
Ser	Ser	Leu	Gln	His	Thr	Thr	Leu	Lys	Pro	Pro	Asp	Val	Thr	Cys	Ile
		100						105					110		
Ser	Lys	Val	Arg	Ser	Ile	Gln	Met	Ile	Val	His	Pro	Thr	Pro	Thr	Pro
	115					120					125				
Ile	Arg	Ala	Gly	Asp	Gly	His	Arg	Leu	Thr	Leu	Glu	Asp	Ile	Phe	His
	130					135					140				
Asp	Leu	Phe	Tyr	His	Leu	Glu	Leu	Gln	Val	Asn	Arg	Thr	Tyr	Gln	Met
145					150				155					160	
His	Leu	Gly	Gly	Lys	Gln	Arg	Glu	Tyr	Glu	Phe	Phe	Gly	Leu	Thr	Pro
			165					170					175		
Asp	Thr	Glu	Phe	Leu	Gly	Thr	Ile	Met	Ile	Cys	Val	Pro	Thr	Trp	Ala
	180						185						190		
Lys	Glu	Ser	Ala	Pro	Tyr	Met	Cys	Arg	Val	Lys	Thr	Leu	Pro	Asp	Arg
	195					200						205			

Thr Trp Thr  
210

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Tyr	Ser	Phe	Ser	Gly	Ala	Phe	Leu	Phe	Ser	Met	Gly	Phe	Leu	Val	Ala
1				5				10						15	
Val	Leu	Cys	Tyr	Leu	Ser	Tyr									
			20												

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 323 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Arg	Tyr	Val	Thr	Lys	Pro	Pro	Ala	Pro	Pro	Asn	Ser	Leu	Asn	Val	Gln
1				5				10						15	
Arg	Val	Leu	Thr	Phe	Gln	Pro	Leu	Arg	Phe	Ile	Gln	Glu	His	Val	Leu
		20						25					30		
Ile	Pro	Val	Phe	Asp	Leu	Ser	Gly	Pro	Ser	Ser	Leu	Ala	Gln	Pro	Val
	35					40					45				
Gln	Tyr	Ser	Gln	Ile	Arg	Val	Ser	Gly	Pro	Arg	Glu	Pro	Ala	Gly	Ala
	50					55				60					
Pro	Gln	Arg	His	Ser	Leu	Ser	Glu	Ile	Thr	Tyr	Leu	Gly	Gln	Pro	Asp
65					70					75				80	
Ile	Ser	Ile	Leu	Gln	Pro	Ser	Asn	Val	Pro	Pro	Pro	Gln	Ile	Leu	Ser
			85					90					95		
Pro	Leu	Ser	Tyr	Ala	Pro	Asn	Ala	Ala	Pro	Glu	Val	Gly	Pro	Pro	Ser
			100					105					110		

Tyr Ala Pro Gln Val Thr Pro Glu Ala Gln Phe Pro Phe Tyr Ala Pro  
           115                          120                          125  
 Gln Ala Ile Ser Lys Val Gln Pro Ser Ser Tyr Ala Pro Gln Ala Thr  
       130                          135                          140  
 Pro Asp Ser Trp Pro Pro Ser Tyr Gly Val Cys Met Glu Gly Ser Gly  
 145                          150                          155                          160  
 Lys Asp Ser Pro Thr Gly Thr Leu Ser Ser Pro Lys His Leu Arg Pro  
                           165                          170                          175  
 Lys Gly Gln Leu Gln Lys Glu Pro Pro Ala Gly Ser Cys Met Leu Gly  
                           180                          185                          190  
 Gly Leu Ser Leu Gln Glu Val Thr Ser Leu Ala Met Glu Glu Ser Gln  
       195                          200                          205  
 Glu Ala Lys Ser Leu His Gln Pro Leu Gly Ile Cys Thr Asp Arg Thr  
       210                          215                          220  
 Ser Asp Pro Asn Val Leu His Ser Gly Glu Glu Gly Thr Pro Gln Tyr  
 225                          230                          235                          240  
 Leu Lys Gly Gln Leu Pro Leu Leu Ser Ser Val Gln Ile Glu Gly His  
                           245                          250                          255  
 Pro Met Ser Leu Pro Leu Gln Pro Pro Ser Gly Pro Cys Ser Pro Ser  
                           260                          265                          270  
 Asp Gln Gly Pro Ser Pro Trp Gly Leu Leu Glu Ser Leu Val Cys Pro  
       275                          280                          285  
 Lys Asp Glu Ala Lys Ser Pro Ala Pro Glu Thr Ser Asp Leu Glu Gln  
       290                          295                          300  
 Pro Thr Glu Leu Asp Ser Leu Phe Arg Gly Leu Ala Leu Thr Val Gln  
 305                          310                          315                          320  
 Trp Glu Ser

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/15847

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/715 C12N15/62 G01N33/566 C07K16/28  
C07K16/42

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 13801 A (SCHERING CORPORATION) 23 June 1994 see claim 12	1-27
A	LIU Y ET AL: "EXPRESSION CLONING AND CHARACTERIZATION OF A HUMAN IL-10 RECEPTOR" JOURNAL OF IMMUNOLOGY, vol. 152, no. 4, 15 February 1994, pages 1821-1829, XP002046437 Also the sequences of human and murine IL-10 receptors see figure 3	1-27



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

2 November 1998

Date of mailing of the international search report

09/11/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Cupido, M

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Interr.      nal Application No

PCT/US 98/15847

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9413801      A	23-06-1994	US    5789192 A	04-08-1998
		AU    5734094 A	04-07-1994
		CN    1090326 A	03-08-1994
		EP    0673420 A	27-09-1995
		JP    7509613 T	26-10-1995
		ZA    9309243 A	09-06-1994
<hr/>			